Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia
NCT03692052Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in thalassemia, sponsored by Agios Pharmaceuticals. Primary endpoint: Hemoglobin Response at 12 weeks. Started Mar 2019; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT03692052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692052.